Antengene Declares Preclinical Study Results on Bispecific Antibody

Antengene Corporation Limited declared that the consequences of its re-clinical examinations on ATG-101 (PD-L1/4-1BB bispecific immunizer) were distributed in Cancer Research in a paper named ATG-101 is a tetravalent PD-L1×4-1BB bispecific neutralizer that stimulates anti-tumor immunity through PD-L1 bar and PD-L1-coordinated 4-1BB enactment. The American Association for Cancer Research (AACR) publishes original studies, reviews, and opinion pieces that significantly impact the cancer research community as a whole and have a five-year influence component of 13.

ATG-101 was developed to conditionally induce 4-1BB stimulation and block the binding of immunosuppressive PD-1/PD-L1, thereby activating anti-tumor immune effectors and delivering enhanced anti-tumor activity with improved safety profile. In a Clinical trial, ATG-101 is being developed in the US, China, and Australia for the treatment of B-cell non-Hodgkin lymphoma (B-NHL) and advanced/metastatic solid tumors.

"Although immune checkpoint inhibitors (ICIs) have transformed cancer treatment, many patients do not achieve desired treatment outcomes due to innate or acquired resistance," said Dr. Bing Hou, Antengene's Head of Discovery Science & Translational Medicine, and the corresponding author of the paper. "While 4-1BB has been recognized as a powerful immune stimulating target, the development of therapeutic 4-1BB agonists has been hampered by hepatotoxicity and suboptimal efficacy. In the Cancer Research paper, we present studies used to characterize the differentiated preclinical features and mechanism of action of ATG-101, a tetravalent PD-L1/4-1BB bispecific antibody. ATG-101 activates 4-1BB+ T cells in a PD-L1-crosslinking dependent manner, which minimizes the hepatotoxicity associated with existing 4-1BB agonists and suppresses the growth of ICI-resistant tumors. We wish to continue contributing to the academic community through publications in the future."